Shares of Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) traded down 5.5% during mid-day trading on Monday . The company traded as low as $4.90 and last traded at $5.00. 518,922 shares were traded during mid-day trading, an increase of 94% from the average session volume of 267,697 shares. The stock had previously closed at $5.29.
The company has a current ratio of 1.13, a quick ratio of 0.88 and a debt-to-equity ratio of 2.84.
Imprimis Pharmaceuticals (NASDAQ:IMMY) last announced its earnings results on Tuesday, November 13th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.03). The firm had revenue of $10.74 million during the quarter. Imprimis Pharmaceuticals had a negative net margin of 16.81% and a negative return on equity of 231.16%.
Several hedge funds and other institutional investors have recently made changes to their positions in IMMY. Northern Trust Corp boosted its position in shares of Imprimis Pharmaceuticals by 145.8% in the 1st quarter. Northern Trust Corp now owns 67,013 shares of the specialty pharmaceutical company’s stock valued at $118,000 after purchasing an additional 39,750 shares during the period. Birchview Capital LP acquired a new stake in Imprimis Pharmaceuticals during the 2nd quarter worth approximately $396,000. Granite Investment Partners LLC lifted its position in Imprimis Pharmaceuticals by 153.8% during the 2nd quarter. Granite Investment Partners LLC now owns 170,962 shares of the specialty pharmaceutical company’s stock worth $376,000 after acquiring an additional 103,607 shares during the period. Ardsley Advisory Partners lifted its position in Imprimis Pharmaceuticals by 42.9% during the 2nd quarter. Ardsley Advisory Partners now owns 100,000 shares of the specialty pharmaceutical company’s stock worth $220,000 after acquiring an additional 30,000 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in Imprimis Pharmaceuticals by 104.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 117,990 shares of the specialty pharmaceutical company’s stock worth $328,000 after acquiring an additional 60,248 shares during the period. 10.03% of the stock is owned by hedge funds and other institutional investors.
About Imprimis Pharmaceuticals (NASDAQ:IMMY)
Imprimis Pharmaceuticals, Inc, an ophthalmology-focused pharmaceutical company, engages in the development, production, and sale of medications to physicians and patients in the United States. It offers ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications.
Recommended Story: Compound Interest
Receive News & Ratings for Imprimis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.